LACNETS TeamJan 261 min readBreaking News: NETTER-2 Trial Supports Lutathera® as 1st Line TreatmentThe NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced...
Lisa Yen, NP, NBC-HWCDec 17, 20226 min readTHESE FOUR LETTERS: PRRT (PART I) An Overview of PRRT Peptide Receptor Radionuclide Therapy Original post April 2, 2019; Updated 12/17/2022 By now, you’ve probably heard...
Lisa Yen, NP, NBC-HWCDec 17, 20222 min readPRRT (PART II)More about PRRT Peptide Receptor Radionuclide Therapy Original post April 24, 2019; Updated 12/17/2022 In our previous article, “These...
